Predictive Modeling Of Alzheimer’s Disease Risk And The Simulated Long -Term Impact Of Covid-19 Severity.
Keywords:
Alzheimer’s Disease, Neurodegenerative disorder, Post-COVID profiles, Cognitive sequelae, Predictive Modeling, Machine LearningAbstract
Alzheimer's disease (AD) is a profoundly challenging neurodegenerative disorder[2], and an expanding body of clinical literature increasingly links the post-acute sequelae of COVID-19 to long-term neurological and cognitive deficits. This computational inquiry investigates the potential impact of long-COVID conditions on the latent risk of developing AD using an advanced machine learning framework. A comprehensive clinical Alzheimer's disease dataset was leveraged for model training and feature extraction[3], while empirical insights from a COVID-19 symptom and cognitive impact dataset were utilized to construct multi-tiered simulated patient profiles. Three distinct classification algorithms—Random Forest[2], Logistic Regression[3], and XGBoost—were trained to predict AD likelihood, with the XGBoost Classifier emerging as the superior predictive model[7]. Feature importance analysis highlighted functional assessments, Activities of Daily Living (ADL), and specific cognitive state examinations as the primary computational drivers of predicted decline[2]. By deploying the trained models against hypothetical post-COVID profiles ranging from mild to severe impairment, a distinct escalation in the predicted Alzheimer's risk probability was observed as post-COVID health markers deteriorated. These findings suggest a compelling structural vulnerability for accelerated cognitive decline in individuals experiencing severe long-term post-COVID conditions[9]. However, because this machine learning simulation serves as an indirect proxy[2], these results underscore an urgent mandate for prospective longitudinal clinical studies to establish definitive causal pathways between viral-induced sequelae and neurodegenerative outcomes[8]..
Downloads
References
[1] Bello-Corral, L. (2025). Evaluating the link between cardiovascular risk and Alzheimer's disease: A comprehensive case-control study in Castilla y León, Spain. Applied Sciences, 15(6), 3409.
[2] Dunk, M. M., & Driscoll, I. (2021). Total cholesterol and APOE-related risk for Alzheimer’s disease in the Alzheimer’s Disease Neuroimaging Initiative. Journal of Alzheimer’s Disease, 85(4), 1519–1528. https://doi.org/10.3233/jad-215091
[3] Emeç, M. (2025). Prediction of Alzheimer's diagnosis with machine learning and innovative feature engineering. Academic Platform Journal of Engineering and Smart Systems, 13(2), 112–124.
[4] Hossain, M. K. (2025). Optimizing Alzheimer's disease prediction through ensemble learning and feature interpretability with SHAP-based feature analysis. Brain and Behavior, 15(8), e12338. https://doi.org/10.1002/brb3.12338
[5] Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019). The role of APOE4 in Alzheimer’s disease: Strategies for future therapeutic interventions. Neuronal Signaling, 3(2), NS20180203. https://doi.org/10.1042/ns20180203
[6] Malar, D. S., Thitilertdecha, P., Ruckvongacheep, K. S., Brimson, S., Tencomnao, T., & Brimson, J. M. (2023). Targeting sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders. CNS Drugs, 37(5), 399–440. https://doi.org/10.1007/s40263-023-01007-6
[7] Nouraeinejad, A. (2023). The link between COVID-19 and Alzheimer disease through neuroinflammation. Clinical Medicine & Research, 21(2), 119–121. https://doi.org/10.3121/cmr.2023.1841
[8] Popa, E. (2025). The molecular mechanisms of cognitive dysfunction in Long COVID: A narrative review. International Journal of Molecular Sciences, 26(11), 5102. https://doi.org/10.3390/ijms26115102
[9] Toups, K. (2022). Precision medicine approach to Alzheimer's disease: Successful pilot project. Journal of Alzheimer's Disease, 88(4), 1411–1421
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.